Kevin E. Ochs v. Commissioner of Social Security Administration

CourtDistrict Court, N.D. Ohio
DecidedMay 19, 2026
Docket1:25-cv-01117
StatusUnknown

This text of Kevin E. Ochs v. Commissioner of Social Security Administration (Kevin E. Ochs v. Commissioner of Social Security Administration) is published on Counsel Stack Legal Research, covering District Court, N.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kevin E. Ochs v. Commissioner of Social Security Administration, (N.D. Ohio 2026).

Opinion

IN THE UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF OHIO EASTERN DIVISION

KEVIN E. OCHS, CASE NO. 1:25-CV-01117-BMB

Plaintiff, JUDGE BRIDGET M. BRENNAN

vs. MAGISTRATE JUDGE DARRELL A. CLAY

COMMISSIONER OF SOCIAL SECURITY REPORT AND RECOMMENDATION ADMINISTRATION,

Defendant.

INTRODUCTION Plaintiff Kevin Ochs challenges the Commissioner of Social Security’s decision denying supplemental security income (SSI) benefits. (ECF #1). The District Court has jurisdiction under 42 U.S.C. §§ 1383(c) and 405(g). This matter was referred to me under Local Civil Rule 72.2 to prepare a Report and Recommendation. (Non-document entry of May 30, 2025). For the reasons below, I recommend the District Court REVERSE and REMAND the Commissioner’s decision for further proceedings consistent with this Report and Recommendation. PROCEDURAL BACKGROUND Mr. Ochs applied for SSI in March 2023, alleging he became disabled that month. (Tr. 264). After his claim was denied initially and on reconsideration, Mr. Ochs requested a hearing before an administrative law judge. (Tr. 160-66, 168-75, 192). In March 2024, Mr. Ochs (represented by counsel) and a vocational expert (VE) testified before the ALJ. (Tr. 35-58). In April 2024, the ALJ determined Mr. Ochs was not disabled. (Tr. 15-34). The Appeals Council denied Mr. Ochs’s request for review, so the ALJ’s decision is the Commissioner’s final decision. (Tr. 1-3; see also 20 C.F.R. § 416.1481). Mr. Ochs timely filed this action. (ECF #1). FACTUAL BACKGROUND

I. Personal and Vocational Evidence Mr. Ochs was 40 years old on his alleged onset date and 41 years old at the administrative hearing. (See Tr. 160). He was enrolled in high school for two years but rarely attended class. (Tr. 299). He later obtained his GED. (Tr. 383). Mr. Ochs has no past relevant work. (Tr. 28). II. Medical Evidence1 Mr. Ochs has a history of anxiety, bipolar disorder, borderline personality disorder, and

post-traumatic stress disorder (PTSD). (Tr. 371). In need of medication management, Mr. Ochs attended a telehealth appointment at LifeStance Health in September 2021. (Tr. 596). During his diagnostic evaluation, Mr. Ochs reported feeling “pretty much stable” on medications but endorsed anxiety with panic attacks, waking during the night, feeling tired even after sleeping, and having nightmares four to five times a week. (Tr. 596, 598). During the assessment, Mr. Ochs was euthymic with full affect with no observed abnormalities in thought process, memory, attention, judgment, or insight. (Tr. 599). At his request, his medications were adjusted. (Id.). Later that

month, Mr. Ochs reported sleeping well but feeling more depressed and having some minor panic attacks. (Tr. 601). His medications were again adjusted. (Tr. 604). On October 7, 2021, Mr. Ochs visited the emergency department for increased depression and anxiety with suicidal ideation. (Tr. 381). There, he endorsed a history of self-harm, increased

1 Apart from a week-long hospital admission, the record shows Mr. Ochs presented exclusively for telehealth appointments. paranoia, and feelings of hopelessness and worthlessness. (Id.). He explained he served four years in prison and was struggling with paranoid thoughts and isolating more since his release. (Tr. 381- 82). Mr. Ochs was hospitalized for seven days during which his treatment team adjusted his

medications. (Tr. 390). At discharge, Mr. Ochs was taking prazosin, propranolol, trazodone, Vistaril, and Wellbutrin XL.2 (Tr. 390-91). In March 2022, Mr. Ochs switched providers at LifeStance Health to nurse practitioner Marissa Nicole Ragon. (Tr. 606). During the first appointment with NP Ragon, Mr. Ochs endorsed anxiety, irritability, and mood swings. (Id.). He also reported longtime symptoms of social phobia including an intense fear of leaving home, being in public, and interacting socially. (Id.).

NP Ragon determined Mr. Ochs’s presentation and history of symptoms were consistent with bipolar disorder, social phobia, generalized anxiety disorder, and PTSD. (Tr. 610). She prescribed lithium and continued his other medications.3 (Tr. 609). The next month, Mr. Ochs denied feeling depressed and endorsed slightly less severe anxiety in general, but reported severe social anxiety, PTSD, panic attacks, poor sleep, and being

2 Prazosin is an alpha-blocker sometimes used to address sleep issues associated with PTSD. Prazosin, MedlinePlus, http://medlineplus.gov/druginfo/meds/a682245.html (last accessed May 18, 2026). Propranolol is a beta blocker sometimes used to treat anxiety. Propranolol, MedlinePlus, http://medlineplus.gov/druginfo/meds/a682607.html (last accessed May 18, 2026). Trazodone is a serotonin modulator used to treat depression. Trazodone, MedlinePlus, http://medlineplus.gov/druginfo/meds/a681038.html (last accessed May 18, 2026). Vistaril is the brand name for hydroxyzine, an antihistamine used to relieve anxiety and tension. Hydroxyzine, MedlinePlus, http://medlineplus.gov/druginfo/meds/a682866.html (last accessed May 18, 2026). Wellbutrin XL is the brand name for bupropion, an antidepressant used to treat depression. Bupropion, MedlinePlus, http://medlineplus.gov/druginfo/meds/a695033.html (last accessed May 18, 2026). 3 Lithium-based medications are used to treat and prevent mania in people with bipolar disorder. See Lithium, MedlinePlus, http://medlineplus.gov/druginfo/meds/a681039.html (last accessed May 18, 2026). startled by loud noises. (Tr. 611). NP Ragon prescribed Remeron and continued his other medications.4 (Tr. 613). In May 2022, Mr. Ochs described less severe anxiety and depression and less frequent

mood swings but endorsed severe symptoms of social anxiety and PTSD. (Tr. 652). NP Ragon increased Remeron and prescribed Luvox.5 (Tr. 617). On June 30, 2022, Mr. Ochs reported feeling “closer to stable,” with less severe depression and anxiety and fewer mood swings. (Tr. 619). NP Ragon increased his dosage of Luvox. (Tr. 621). Those improvements continued into July 2022, when Mr. Ochs reported feeling less anxious “generally and socially,” and denied feeling depressed. (Tr. 623). He described excessive daytime sleepiness shortly after increasing Luvox. (Id.). NP Ragon reduced Remeron and directed

Mr. Ochs to take Luvox in the evening. (Tr. 625). Mr. Ochs felt more anxious later that month after his grandfather died. (Tr. 627). NP Ragon noted: “Luvox is proving to be effective for reducing social phobia/anxiety symptoms. This is evidenced by his ability to tolerate being around many people at his grandfather’s funeral.” (Id.). Mr. Ochs described “slightly less severe” daytime sleepiness with the reduced dose of Remeron. (Id.). NP Ragon further reduced the dosage of Remeron to address the side effects. (Tr. 629).

In August 2022, Mr. Ochs endorsed mild depression and more intense anxiety that causes increased irritability, but reported Remeron was effective for sleep and he was not overly drowsy

4 Remeron is the brand name for mirtazapine, an antidepressant used to treat depression. Mirtazapine, MedlinePlus, http://medlineplus.gov/druginfo/meds/a697009.html (last accessed May 18, 2026). 5 Luvox is the brand name for fluvoxamine, a selective serotonin reuptake inhibitor used to treat social anxiety disorder (extreme fear of interacting with others or performing in front of others that interferes with normal life). Fluvoxamine, MedlinePlus, http://medlineplus.gov/ druginfo/meds/a695004.html (last accessed May 18, 2026). during the day. (Tr. 631).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Angela M. Jones v. Commissioner of Social Security
336 F.3d 469 (Sixth Circuit, 2003)
Robert M. Wilson v. Commissioner of Social Security
378 F.3d 541 (Sixth Circuit, 2004)
Blakley v. Commissioner of Social Security
581 F.3d 399 (Sixth Circuit, 2009)
Fleischer v. Astrue
774 F. Supp. 2d 875 (N.D. Ohio, 2011)
Bledsoe v. Barnhart
165 F. App'x 408 (Sixth Circuit, 2006)
Phillip Stacey v. Commissioner of Social Security
451 F. App'x 517 (Sixth Circuit, 2011)
Jacqueline Brooks v. Commissioner of Social Securit
531 F. App'x 636 (Sixth Circuit, 2013)
Griffith v. Commissioner of Social Security
582 F. App'x 555 (Sixth Circuit, 2014)
Anthony Reeves v. Comm'r of Social Security
618 F. App'x 267 (Sixth Circuit, 2015)
Sorrell v. Commissioner of Social Security
656 F. App'x 162 (Sixth Circuit, 2016)
Crum v. Commissioner of Social Security
660 F. App'x 449 (Sixth Circuit, 2016)
United States v. Patrick Wandahsega
924 F.3d 868 (Sixth Circuit, 2019)
Randy Berkshire v. Debra Dahl
928 F.3d 520 (Sixth Circuit, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
Kevin E. Ochs v. Commissioner of Social Security Administration, Counsel Stack Legal Research, https://law.counselstack.com/opinion/kevin-e-ochs-v-commissioner-of-social-security-administration-ohnd-2026.